Camp4 Therapeutics Corp. Stock Price, News & Analysis

CAMP4 (Nasdaq: CAMP) entered a strategic research, collaboration and license agreement with GSK on Dec 18, 2025 to apply CAMP4’s RAP Platform® to identify antisense oligonucleotide (ASO) candidates for neurodegenerative and kidney diseases.

Under the deal CAMP4 will receive $17.5 million upfront, is eligible for additional milestone payments and tiered royalties, and will deliver discovery-stage regRNA-targeting ASOs while GSK will lead development and commercialization.

CAMP4 Therapeutics (Nasdaq: CAMP) announced on December 11, 2025 that its Board approved inducement grants under Nasdaq Listing Rule 5635(c)(4).

The Board granted non-qualified stock options to purchase an aggregate of 92,000 shares to four newly hired employees. Each option has a ten-year term and an exercise price of $6.01, equal to CAMP4’s closing share price on the grant date.

The options vest over four years with 25% vesting at the one-year anniversary and the remainder vesting in 36 equal monthly installments, subject to continued service and the terms of an Inducement Option Award Agreement.

CAMP4 Therapeutics (Nasdaq: CAMP) announced an inducement stock option grant on November 12, 2025 to a newly hired employee under Nasdaq Listing Rule 5635(c)(4).

The Board granted a non‑qualified option to purchase 80,000 shares with a 10‑year term and an exercise price of $4.39, equal to the closing price on the grant date. The option vests over four years: 25% after one year, then the remainder in 36 monthly installments, subject to continued service, and is governed by an Inducement Option Award Agreement.

CAMP (Nasdaq: CAMP) reported Q3 2025 results and corporate updates on Nov 6, 2025. Key items include a private placement initial closing of $50M (up to $100M total) that management says extends runway into 2027, and cash and marketable securities of $75.3M as of Sept 30, 2025 (up from $39.1M on June 30, 2025).

Clinical progress: initiated GLP toxicology studies for CMP-002 to support a planned Phase 1/2 filing with potential trial start as early as H2 2026; completed MAD analysis for CMP-001 showing favorable safety and PK and received a Netherlands CTA to start a Phase 1b in OTC heterozygotes. Q3 operating items: R&D $9.4M, G&A $4.6M, net loss $15.1M.

CAMP4 Therapeutics (Nasdaq: CAMP) has initiated GLP toxicology studies for CMP-SYNGAP-01, their lead product candidate targeting SYNGAP1-related disorders. The company aims to submit a clinical trial application that could lead to a Phase 1/2 clinical trial beginning in H2 2026.

Preclinical studies have shown promising results, with CMP-SYNGAP-01 successfully restoring SYNGAP1 protein levels in mouse models and increasing protein levels in relevant brain regions of non-human primates. SYNGAP1-related disorders, affecting 0.5% to 1.0% of intellectual disability cases, currently lack FDA-approved disease-modifying treatments.

CAMP4 Therapeutics (NASDAQ: CAMP) has secured an oversubscribed private placement of up to $100 million to advance its SYNGAP1 program. The financing includes $50 million in upfront proceeds and potential for an additional $50 million tied to achieving specific milestones, including regulatory clearance for a Phase 1/2 clinical trial.

The initial financing comprises 26,681,053 shares of common stock at $1.53 per share, with additional shares for directors and employees at $1.65, and pre-funded warrants. The placement is led by Coastlands Capital, with participation from investors including Janus Henderson, Balyasny Asset Management, and Vivo Capital.

Alongside this financing, Doug Williams, Ph.D., has been appointed as Board Chair, and Daniel Tardiff, Ph.D., will become Chief Scientific Officer effective October 1, 2025. The company plans to initiate its Phase 1/2 clinical trial for SYNGAP1-related disorders as early as 2H 2026.

CAMP4 Therapeutics (NASDAQ:CAMP) reported Q2 2025 financial results and corporate updates, highlighting progress in its RNA-targeting therapeutics pipeline. The company presented positive translational data for its SYNGAP1-related disorders program at the ASGCT Annual Meeting, demonstrating efficacy in mouse models and increased protein levels in non-human primates.

Key developments include plans to initiate GLP toxicology studies for CMP-SYNGAP-01 in Q3 2025, with potential Phase 1/2 trial initiation in H2 2026. The company completed dosing in the third MAD cohort for CMP-CPS-001, with comprehensive data expected in Q4 2025. Financial position shows $39.1 million in cash and equivalents, with Q2 R&D expenses of $10.3 million and a net loss of $12.6 million.

CAMP4 Therapeutics (NASDAQ: CAMP) presented promising data from two key programs at the 28th ASGCT Annual Meeting. For their SYNGAP1-related disorders program, CMP-SYNGAP-01 demonstrated increased SYNGAP1 protein levels in both haploinsufficient mice and non-human primates, with successful rescue of behavioral phenotypes. In mice, the treatment restored protein levels to near normal range and improved motor and spatial learning defects. In NHPs, biweekly intrathecal injections achieved a ~1.5-fold protein increase across relevant brain regions. For their Urea Cycle Disorders (UCDs) program, Phase 1 clinical trial data of CMP-CPS-001 showed favorable safety profiles in healthy volunteers. The trial enrolled 48 participants across four SAD cohorts, with no serious adverse events reported. Preclinical data showed promising results in both mice and NHPs, with up to 40% increase in ureagenesis in NHPs and dose-dependent reductions in ammonia levels in mice.

CAMP4 Therapeutics (NASDAQ: CAMP) reported Q1 2025 financial results and corporate updates. The company completed dosing in three multiple ascending dose (MAD) cohorts for CMP-CPS-001 in Urea Cycle Disorders, with safety and other data expected in Q4 2025. CAMP4 nominated CMP-SYNGAP-01 as a development candidate for SYNGAP1-related disorders, with GLP toxicology studies planned for 2025. The company submitted a CTA in Europe for a Phase 1b trial in female OTC heterozygotes. Financially, CAMP4 reported cash position of $49.3 million, R&D expenses of $10.1 million, and a net loss of $12.4 million for Q1 2025. The company will receive a $0.6 million milestone payment from Fulcrum Therapeutics under their DBA program license agreement, with potential future payments up to $70 million plus royalties.